Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Socioeconomic Disparities in Preemptive Kidney Transplant Rates in Children
Kizilbash, Sarah J. , Wi, Chung‐Il , Roy, Madison, McKinney, Warren T. , Amaral, Sandra , Riad, Samy , Juhn, Young J. , Kizilbash, Sarah , Wi, Chung-Ii , Juhn, Young, Riad, Samy M. , McKinney, Warren , Amaral, Sandra G.

Kidney360 | April 7, 2025 | Volume: 6 | Issue: 7 | Pages: 1188-1197

10.34067/kid.0000000802 | PMID 40193218 Get It

Key Points Pediatric preemptive kidney transplantation rates in the United States vary by socioeconomic status (SES). The HOUsing-based index of SES, an individual-level SES measure derived from residential addresses, effectively predicts pediatric preemptive kidney transplant rates. Background Preemptive kidney transplantation in children is associated with better patient and graft survival compared with transplants after dialysis. However, preemptive kidney transplantation rates in children remain low. This study aimed to evaluate the effect of socioeconomic status (SES) on preemptive transplantation in children. Methods Our study included 173 Minnesota-resident pediatric kidney transplant recipients (younger than 18 years) transplanted at the University of Minnesota from 2010 to 2020. Using the HOUsing-based index of SES (HOUSES) index, a validated, individual SES measure based on housing units categorized into quartiles (Q1: lower SES; Q2–Q4: higher SES), we applied mixed-effects multivariable logistic models to examine the effects of HOUSES on preemptive kidney transplants and pretransplant dialysis duration. Results Of 173 pediatric kidney transplant recipients, 46 (26.6%) received a preemptive transplant, and of 109 recipients with dialysis duration data, 39 (35.8%) received dialysis for >1 year. After adjusting for age at kidney failure, sex, donor type, insurance type, and underlying cause of kidney failure, we observed significantly lower odds of preemptive transplantation among Q1 recipients compared with Q2–4 recipients (adjusted odds ratio, 0.31; 95% confidence interval, 0.11 to 0.90; P = 0.03). Conclusions Using the HOUSES index, we found significant socioeconomic disparities in preemptive kidney transplantation rates among children.
Report of Hidradenitis Suppurativa in an Individual Affected by Rubinstein‐Taybi Syndrome
Wanberg, Erik J. , Fletcher, Kathleen M., Aghazadeh, Nessa , Aghazadeh Mohandesi, Nessa , Alavi, Afsáneh

Pediatric Dermatology | April 7, 2025 | Volume: 42 | Issue: 4 | Pages: 855-857

10.1111/pde.15906 | PMID 40192214 Get It

ABSTRACTRubinstein‐Taybi syndrome (RTS) is a rare genetic disorder featuring craniofacial abnormalities, intellectual disability, and multi‐organ involvement, including increased risk of keloid formation, pilomatricomas, and hypertrichosis. Hidradenitis suppurativa (HS), a chronic inflammatory skin condition characterized by recurrent abscess formation and draining tunnels, has never been described in a patient affected by RTS. In this report, we detail the history of a 32‐year‐old male with RTS and refractory Hurley stage III HS and discuss the important considerations and risks of managing this unique patient population.
Reinterpretation of outside imaging and review at hepatobiliary tumor board: impact on diagnosis and management of patients with hepatobiliary neoplasms
Nguyen, Michelle , Sheedy, Shannon P. , Heiken, Jay P. , Ehman, Eric C. , Flicek, Kristina T. , Olson, Mike, Suman, Garima , Kelm, Zachary S. , Nehra, Avinash , Fleming, Chad J. , Kurup, Nick, Weisbrod, Adam J. , Fidler, Jeff, Nguyen, Michelle T. , Venkatesh, Sudhakar K. , Welle, Christopher L. , Adamo, Daniel A. , Navin, Patrick J. , Olson, Michael C. , Hibbert, Rebecca , Wells, Michael , Kurup, A. Nicholas , Fidler, Jeff L.

No container title available | April 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6221151/v1 Get It

Abstract Objectives: Radiologist participation in multidisciplinary tumor board can be time-consuming and demanding, requiring substantial preparation. Anecdotally radiologist participation is felt to help identify discrepancies in previous interpretations; however, there are limited data assessing the actual impact of their tumor board review on patient management. This prospective study aims to evaluate how the reinterpretation of outside imaging and review at hepatobiliary tumor board (HBTB) affects the diagnosis and management of patients with hepatobiliary neoplasms. Methods: This prospective analysis included all patients presented at the weekly HBTB between 6/13/2023 - 6/25/2024. One radiologist reviewed the available reports of outside imaging, the local reinterpretation of outside imaging, the updated local imaging, and documented conclusions from discussion of the case at HBTB. HBTB included 4 radiologists who had reviewed each case. Discrepancies (presence/absence, number, and reasons for) were recorded. When discrepancies occurred, the impact on patient management (5-point Likert scale) was determined by two of the radiologists present at the HBTB in consensus, with input from clinicians if needed. A six-month follow-up was performed to confirm suspected diagnoses. Results: 208 cases (128 males, 104 chronic liver disease patients) were presented at HBTB. Disagreements in the detection or characterization of lesions were found in 59/208 (28.4%) of cases. A change in management occurred in 38/59 (64.6%) of these discrepant cases. In cases with recorded discrepancies in which follow-up confirmation was available, the final interpretation was confirmed in 34/41 (82.9%) of cases. Conclusion: Our study found a discrepant interpretation in nearly one-third of cases presented at a weekly HBTB and a resultant change in management in 65% of those cases. These findings highlight the importance of reinterpretation of prior imaging studies and the presence of radiologists at HBTB to guide optimal patient management.
Cancer Incidence and Survival after Emergency Department Care in the U.S. Midwest: An Opportunity for Cancer Interception
Sherman, Mark E. , Heckman, Michael G. , DeStephano, Christopher C. , White, Launia J. , Pfeiffer, Ruth M. , St Sauver, Jennifer L , Pfeiffer, Ruth M , Heckman, Michael G , DeStephano, C C , Sherman, Mark E , Sauver, Jennifer L. St.

Cancer Prevention Research | April 7, 2025 | Volume: 18 | Issue: 7 | Pages: 413-421

10.1158/1940-6207.capr-24-0426 | PMID 40192659 Get It

Abstract Historically, cancers diagnosed via the emergency department (ED) portend a poor prognosis. Recent data from the United States are sparse, and analyses of cancers detected in the years following ED visits are lacking. Thus, we analyzed data from nine rural U.S. Midwest counties included within the population-based Rochester Epidemiology Project (2015–2021). Participants without a history of cancer (N = 42,074) who did not receive ED care were matched 1:1 to ED participants on the date of ED visit, age, sex, race, ethnicity, and county of residence. Analyses were restricted to participants with records ≤2 years prior to ED or index visit and ≥30 days after. HRs and 95% confidence intervals (CI) comparing cancer incidence and deaths among ED and non-ED participants were estimated from Cox proportional hazards regression models, either unadjusted or adjusted for covariates. Cumulative cancer incidence curves accounting for competing risks of death and survival (all cause and cancer-specific) were estimated. The median follow-up was 6.3 years, with 2,719 (6.46%) cancers diagnosed among ED participants and 3,139 (7.46%) among non-ED participants. ED participants experienced lower cancer risk overall (HRAdjusted = 0.70; 95% CI, 0.66–0.74; P = 8.89 × 10−31), specifically for breast cancer, prostate cancer, melanoma, and secondary cancers. Cancer-specific mortality was higher among ED participants (HRAdjusted = 1.76; 95% CI, 1.49–2.08; P = 3.62 × 10−11). Compared with non-ED participants, ED participants experienced a lower incidence of cancer but higher overall cancer-specific mortality, suggesting that subsets of ED patients may benefit from postvisit preventive interventions. Prevention Relevance: This cohort analysis shows that cancer incidence over 6 years was lower among participants after an ED visit than among matched non-ED participants, whereas cancer-specific mortality was higher in the ED group (HRAdjusted = 1.76; 95% CI, 1.49–2.08; P = 3.62 × 10−11), suggesting the potential benefit of preventive interventions.
Aging-dependent dysregulation of EXOSC2 is maintained in cancer as a dependency
Skamagki, Maria , Hacisuleyman, Ezgi , Galleti, Giuseppe, Vinagolu, Rajasekhar, Cha, HyoKyeong, Ata, Deniz, Kim, Jong-Jin , Weiskittel, Taylor M. , Diop, Mame, Aung, Thiri, Latto, Michael Del , Kim, Amanda S., Li, Zhuoning , Zhao, Rui , Hendrickson, Ronald C. , Bott, Matthew J. , Hu, Li , Romesser, Paul B , Smith, J Joshua , Giannakakou, Paraskevi , Zhang, Cheng, Wu, Chao , Cha, HyoKyeong, Kim, Jongjin, Diop, Mame, Aung, Thiri, Miele, Matthew M. , Tang, Laura H. , Hendrickson, Ronald C. , Romesser, Paul B. , Smith, J. Joshua , Darnell, Robert B. , Li, Hu, Kim, Kitai

No container title available | April 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.04.04.647279 | PMID 40236131 Get It

Abstract Reprogramming of aged donor tissue cells into induced pluripotent stem cells (A-iPSC) preserved the epigenetic memory of aged-donor tissue, defined as genomic instability and poor tissue differentiation in our previous study. The unbalanced expression of RNA exosome subunits affects the RNA degradation complex function and is associated with geriatric diseases including premature aging and cancer progression. We hypothesized that the age-dependent progressive subtle dysregulation of EXOSC2 (exosome component 2) causes the aging traits (abnormal cell cycle and poor tissue differentiation). We used embryonic stem cells as a tool to study EXOSC2 function as the aging trait epigenetic memory determined in A-iPSC because these aging traits could not be studied in senesced aged cells or immortalized cancer cells. We found that the regulatory subunit of PP2A phosphatase, PPP2R5E, is a key target of EXOSC2 and this regulation is preserved in stem cells and cancer.
Algorithm to Identify Type 2 Diabetes Using Electronic Health Record and Self-Reported Data
Varghese, Ben , Girardo, Marlene , Gupta, Ruchi , Duellman, Madison, Egan, Aoife M. , Vella, Adrian , Bailey, Kent R. , Varghese, Ben T , Egan, A M , Vella, Adrian , Dugani, Sagar B , Gupta, Ruchi, Fischer, Karen M. , Mielke, Michelle M. , Olson, Janet E. , Dugani, Sagar B.

Metabolic Syndrome and Related Disorders | April 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1089/met.2024.0133 | PMID 40192533 Get It

Sex Hormones in Allergic Disease: Overview and Spotlight on Asthma in Pregnancy
Chong, Albert C. , Shihab, Sara, Vegunta, Suneela , Chong, Albert

Journal of Women's Health | April 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1089/jwh.2025.0170 | PMID 40192528 Get It

Economic Impact Model of Incorporating Cxbladder Monitor in the Surveillance of Nonmuscle Invasive Bladder Cancer
Tyson, Mark D. , Sfakianos, John P. , Shoskes, Daniel A., Muench, Tobias, Seemann, K. , Saunders, Rhodri , Daneshmand, Siamak

JU Open Plus | April 7, 2025 | Volume: 3 | Issue: 4 | Pages: No page available

10.1097/ju9.0000000000000271 Get It

Introduction: Guideline recommended surveillance of nonmuscle invasive bladder cancer (NMIBC) involves frequent cystoscopies. Cxbladder Monitor (CxbM) is a noninvasive urinary genomic test with high negative predictive value for NMIBC recurrence. Incorporation of CxbM into surveillance could reduce the frequency, burden, and cost of surveillance. We studied this impact using a theoretical health economic model. Materials and Methods: A Markov model for disease dynamics and decision tree model for surveillance pathways were created for 100 patients with theoretical NMIBC risk stratified by AUA criteria over 5 years from diagnosis. In the standard of care (SOC) arm, cystoscopy was performed per AUA guidelines. In the CxbM surveillance arm, CxbM was used starting 9 months after diagnosis. If positive, cystoscopy was performed per guidelines, but if negative, the cystoscopy was not performed and on the next scheduled encounter. Primary outcome was total budgetary impact. Additional outcomes included number of diagnostic tests, test-related complications, and patients with delayed diagnosis. Results: Compared with SOC, CxbM reduced mean total costs by $68,621 for 100 patients over 5 years or $137.24 per patient per year. Cystoscopy was reduced by 129 (0.31 per patient per year), and there was no difference in delayed cancer diagnosis. Using a probabilistic model, the median cost reduction per patient per year was $160 (95% credible interval −520 to 109) with 86.2% probability of cost savings. Conclusions: In this Markov model, incorporation of CxbM into surveillance for NMIBC reduced cystoscopy without negative impact on cancer detection with cost savings for the majority of simulations run.
Treatment of Clostridioides difficile: The Times They Are Changing
Feuerstadt, Paul , Allegretti, Jessica R. , Khanna, Sahil , Feuerstadt, Paul

American Journal of Gastroenterology | April 7, 2025 | Volume: 120 | Issue: 11 | Pages: 2468-2470

10.14309/ajg.0000000000003445 | PMID 40192143 Get It

Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant‐Eligible Multiple Myeloma: A Systematic Review and Meta‐Analysis
Channar, Aneeta , Naqvi, Syed Arsalan Ahmed , Khan, Muhammad Ali , Bibi, Arifa, Saxena, Akshat , Tripathi, Nikita , Iftikhar, Ahmad , Raina, Ammad, Khakwani, Kaneez Zahra Rubab, Riaz, Irbaz Bin , Husnain, Muhammad

Cancer Reports | April 7, 2025 | Volume: 8 | Issue: 4 | Pages: No page available

10.1002/cnr2.70171 | PMID 40176408 Get It

ABSTRACTBackgroundThe treatment landscape for multiple myeloma continues to evolve. Recently, the addition of anti‐CD38 monoclonal antibodies (mAbs) to the triplet regimen, comprising a proteasome inhibitor, an immunomodulatory agent, and a steroid, for transplant‐eligible newly diagnosed multiple myeloma (TENDMM) has shown promising results.AimsTo evaluate the overall efficacy and safety of quadruplet therapy with an anti‐CD38 mAb compared to a triplet regimen.MethodsA systematic search of Medline, Scopus, and EMBASE databases from inception to July 2024 identified relevant randomized controlled trials (RCTs). Efficacy and safety outcomes were derived using random‐effects meta‐analysis. Summarized outcomes include hazard ratios (HR) for progression‐free survival (PFS) and overall survival (OS), odds ratios (OR) for response rates, measurable residual disease (MRD) negativity rate, and grade 3 or higher adverse events (G ≥ 3 AEs).ResultsFive RCTs involving 2963 patients were included. A statistically significant PFS was observed for quadruplet therapy when compared to the triplet regimen (HR 0.44; 95% Confidence Interval [CI] 0.35–0.56). PFS benefit was consistent for the standard risk (SR) group (HR 0.38; 95% CI 0.27–0.52) and high risk (HiR) group (HR 0.62; 95% CI 0.41–0.92). No statistically significant benefit was observed for OS (HR 0.55; 95% CI 0.28–1.08). A statistically significant benefit was observed for the overall response rate (OR 1.77; 95% CI 1.02–3.06) and MRD negativity rate (OR 2.67; 95% CI 1.79–3.99). No significant differences were observed for G ≥ 3 AE (OR 1.21; 95% CI 0.92–1.58), lymphopenia (OR 1.09; 95% CI 0.62–1.89), and anemia (OR 1.06; 95% CI 0.83–1.37). However, a significantly increased risk was observed for all‐grade thrombocytopenia (OR 1.64; 95% CI 1.37–1.97), neutropenia (OR 2.24; 95% CI 1.67–3.02) and infections (OR 1.88; 95% CI 1.07–3.31).ConclusionQuadruplet therapy demonstrated a favorable efficacy and safety profile, with consistent benefit across subgroups. The findings support its potential as the new standard of care for TENDMM.